Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

HIV Infections 13Acquired Immunodeficiency Syndrome 13Sarcoma, Kaposi 9Lymphoma 9Lymphoma, Non-Hodgkin 4AIDS-Related Opportunistic Infections 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Multi-centric Castleman's Disease 2Epstein-Barr Virus Infections 2Precancerous Conditions 1Neoplasms 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphadenopathy 1Leukemia-Lymphoma, Adult T-Cell 1Hodgkin Disease 1Herpesviridae Infections 1HTLV-I Infections 1Dendritic Cell Sarcoma, Interdigitating 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1AIDS-Related Complex 1

Interventions

Zidovudine 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Herpesviridae Infections × Zidovudine × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡